对我国医药企业自主创新演化机制的分析

To Analyse on Evolved Mechanism of Chinese Medicine Enterprises Active Innovation

自主创新是当前商业界和学术界研究比较热的话题。政府相应地制定了一系列的政策和法规来鼓励企业进行自主创新。在这种背景下,我国的医药企业也积极响应国家的政策进行自主创新。然而,医药企业创新在实际操作中的行动方向差异很大。针对这种差异,笔者将医药企业创新划分成新功能创新和新设计创新两种,并且通过对一系列的数据和资料分析后,发现我国的医药企业的创新并非实质上的自主创新即新功能创新,而是新设计创新。文中对产生这种局面的演化机制进行了分析。

Innovation is the hot topic talked by the business and academy community. The government has formulated a series of relevant policies and regulations to encourage enterprises to innovate, in this context, pharmaceutical enterprises in China have responded positively to the national policy of innovation. However, in actual operation, the innovation of pharmaceutical enterprises has many differences in the course of the action. In view of these differences, the author will divided innovation into two kinds： innovation of new functions and innovation of new designs. Through the analysis of a series of data and information, innovation of China＇s pharmaceutical enterprises has been founded actually not the innovation of new functions, but the innovation of new designs. The text has analysized the mechanism to produce the evolution of this situation.